# Geistlich Pharma North America acquires Lynch Biologics

Geistlich Pharma North America acquired Lynch Biologics, developer of GEM 21S, a recombinant growth factor product for oral regenerative surgery. The acquisition strengthens Geistlich's regenerative product portfolio.

- Type: Acquisition
- Announced: 2022-10-27
- Where: United States
- Status: completed
- Products: GEM 21S, recombinant growth factor product
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Geistlich Pharma North America](https://endata.com/companies/66187.md) (acquirer)
- [Lynch Biologics](https://endata.com/companies/66188.md) (target)

## Sources

- [biospace.com](https://www.biospace.com/geistlich-pharma-north-america-inc-acquires-lynch-biologics-llc-a-biologics-and-tissue-engineering-company), 2022-10-27: "We're delighted to welcome Lynch Biologics to our Geistlich family and to have the opportunity to work with Dr. Lynch."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.